Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has decided to close its Holywell, U.K., facility, which provides chemical development services and small- and large-scale manufacturing services of active pharmaceutical ingredients (API) and intermediates.

AMRI will transition activities at the Holywell site to other facilities within the AMRI network and plans to cease operations at the site by the end of 2015. Closure is expected to affect approximately 62 positions.